Cargando…

Inhibition of (pro)renin Receptor Contributes to Renoprotective Effects of Angiotensin II Type 1 Receptor Blockade in Diabetic Nephropathy

Aims: Renal renin-angiotensin system (RAS) plays a pivotal role in the development of diabetic nephropathy (DN). Angiotensin II (Ang II) type 1 receptor (AT(1)R) blockade elevates (pro)renin, which may bind to (pro)renin receptor (PRR) and exert receptor-mediated, angiotensin-independent profibrotic...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Lin, An, Xiao-Fei, Ruan, Xin, Huang, Dong-Dong, Zhou, Li, Xue, Hong, Lu, Li-Min, He, Ming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5635681/
https://www.ncbi.nlm.nih.gov/pubmed/29056916
http://dx.doi.org/10.3389/fphys.2017.00758
_version_ 1783270337955233792
author Zhang, Lin
An, Xiao-Fei
Ruan, Xin
Huang, Dong-Dong
Zhou, Li
Xue, Hong
Lu, Li-Min
He, Ming
author_facet Zhang, Lin
An, Xiao-Fei
Ruan, Xin
Huang, Dong-Dong
Zhou, Li
Xue, Hong
Lu, Li-Min
He, Ming
author_sort Zhang, Lin
collection PubMed
description Aims: Renal renin-angiotensin system (RAS) plays a pivotal role in the development of diabetic nephropathy (DN). Angiotensin II (Ang II) type 1 receptor (AT(1)R) blockade elevates (pro)renin, which may bind to (pro)renin receptor (PRR) and exert receptor-mediated, angiotensin-independent profibrotic effects. We therefore investigated whether PRR activation leads to the limited anti-fibrotic effects of AT(1)R blockade on DN, and whether PRR inhibition might ameliorate progression of DN. Methods: To address the issue, the expression of RAS components was tested in different stages of streptozotocin (STZ)-induced diabetic rats (6, 12, and 24 weeks) and 6-week AT(1)R blockade (losartan) treated diabetic rats. Using the blocker for PRR, the handle region peptide (HRP) of prorenin, the effects of PRR on high glucose or Ang II-induced proliferative and profibrotic actions were evaluated by measurement of cell proliferation, matrix metalloproteinase-2 (MMP-2) activity, activation of extracellular signal-regulated kinase 1/2 (ERK1/2) and transforming growth factor-β1 (TGF-β1) expression in rat mesangial cells (MCs). Results: PRR was downregulated in the kidneys of different stages of diabetic rats (6, 12, and 24 weeks). Moreover, 6-week losartan treatment further suppressed PRR expression via upregulating AT(2)R, and ameliorated diabetic renal injury. HRP inhibited high glucose and Ang II-induced proliferative and profibrotic effects in MCs through suppressing TGF-β1 expression and activating MMP-2. Meanwhile, HRP enhanced losartan's anti-fibrotic effects through further inhibiting phosphorylation of ERK1/2 and TGF-β1 expression. Moreover, the inhibitive effect of HRP on Ang II-induced TGF-β1 expression depended on the regulation of PRR expression by AT(2)R. Conclusions: Our findings suggest that inhibition of PRR contributes to renoprotection against diabetic nephropathy by AT(1)R blockade.
format Online
Article
Text
id pubmed-5635681
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-56356812017-10-20 Inhibition of (pro)renin Receptor Contributes to Renoprotective Effects of Angiotensin II Type 1 Receptor Blockade in Diabetic Nephropathy Zhang, Lin An, Xiao-Fei Ruan, Xin Huang, Dong-Dong Zhou, Li Xue, Hong Lu, Li-Min He, Ming Front Physiol Physiology Aims: Renal renin-angiotensin system (RAS) plays a pivotal role in the development of diabetic nephropathy (DN). Angiotensin II (Ang II) type 1 receptor (AT(1)R) blockade elevates (pro)renin, which may bind to (pro)renin receptor (PRR) and exert receptor-mediated, angiotensin-independent profibrotic effects. We therefore investigated whether PRR activation leads to the limited anti-fibrotic effects of AT(1)R blockade on DN, and whether PRR inhibition might ameliorate progression of DN. Methods: To address the issue, the expression of RAS components was tested in different stages of streptozotocin (STZ)-induced diabetic rats (6, 12, and 24 weeks) and 6-week AT(1)R blockade (losartan) treated diabetic rats. Using the blocker for PRR, the handle region peptide (HRP) of prorenin, the effects of PRR on high glucose or Ang II-induced proliferative and profibrotic actions were evaluated by measurement of cell proliferation, matrix metalloproteinase-2 (MMP-2) activity, activation of extracellular signal-regulated kinase 1/2 (ERK1/2) and transforming growth factor-β1 (TGF-β1) expression in rat mesangial cells (MCs). Results: PRR was downregulated in the kidneys of different stages of diabetic rats (6, 12, and 24 weeks). Moreover, 6-week losartan treatment further suppressed PRR expression via upregulating AT(2)R, and ameliorated diabetic renal injury. HRP inhibited high glucose and Ang II-induced proliferative and profibrotic effects in MCs through suppressing TGF-β1 expression and activating MMP-2. Meanwhile, HRP enhanced losartan's anti-fibrotic effects through further inhibiting phosphorylation of ERK1/2 and TGF-β1 expression. Moreover, the inhibitive effect of HRP on Ang II-induced TGF-β1 expression depended on the regulation of PRR expression by AT(2)R. Conclusions: Our findings suggest that inhibition of PRR contributes to renoprotection against diabetic nephropathy by AT(1)R blockade. Frontiers Media S.A. 2017-10-06 /pmc/articles/PMC5635681/ /pubmed/29056916 http://dx.doi.org/10.3389/fphys.2017.00758 Text en Copyright © 2017 Zhang, An, Ruan, Huang, Zhou, Xue, Lu and He. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Physiology
Zhang, Lin
An, Xiao-Fei
Ruan, Xin
Huang, Dong-Dong
Zhou, Li
Xue, Hong
Lu, Li-Min
He, Ming
Inhibition of (pro)renin Receptor Contributes to Renoprotective Effects of Angiotensin II Type 1 Receptor Blockade in Diabetic Nephropathy
title Inhibition of (pro)renin Receptor Contributes to Renoprotective Effects of Angiotensin II Type 1 Receptor Blockade in Diabetic Nephropathy
title_full Inhibition of (pro)renin Receptor Contributes to Renoprotective Effects of Angiotensin II Type 1 Receptor Blockade in Diabetic Nephropathy
title_fullStr Inhibition of (pro)renin Receptor Contributes to Renoprotective Effects of Angiotensin II Type 1 Receptor Blockade in Diabetic Nephropathy
title_full_unstemmed Inhibition of (pro)renin Receptor Contributes to Renoprotective Effects of Angiotensin II Type 1 Receptor Blockade in Diabetic Nephropathy
title_short Inhibition of (pro)renin Receptor Contributes to Renoprotective Effects of Angiotensin II Type 1 Receptor Blockade in Diabetic Nephropathy
title_sort inhibition of (pro)renin receptor contributes to renoprotective effects of angiotensin ii type 1 receptor blockade in diabetic nephropathy
topic Physiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5635681/
https://www.ncbi.nlm.nih.gov/pubmed/29056916
http://dx.doi.org/10.3389/fphys.2017.00758
work_keys_str_mv AT zhanglin inhibitionofproreninreceptorcontributestorenoprotectiveeffectsofangiotensiniitype1receptorblockadeindiabeticnephropathy
AT anxiaofei inhibitionofproreninreceptorcontributestorenoprotectiveeffectsofangiotensiniitype1receptorblockadeindiabeticnephropathy
AT ruanxin inhibitionofproreninreceptorcontributestorenoprotectiveeffectsofangiotensiniitype1receptorblockadeindiabeticnephropathy
AT huangdongdong inhibitionofproreninreceptorcontributestorenoprotectiveeffectsofangiotensiniitype1receptorblockadeindiabeticnephropathy
AT zhouli inhibitionofproreninreceptorcontributestorenoprotectiveeffectsofangiotensiniitype1receptorblockadeindiabeticnephropathy
AT xuehong inhibitionofproreninreceptorcontributestorenoprotectiveeffectsofangiotensiniitype1receptorblockadeindiabeticnephropathy
AT lulimin inhibitionofproreninreceptorcontributestorenoprotectiveeffectsofangiotensiniitype1receptorblockadeindiabeticnephropathy
AT heming inhibitionofproreninreceptorcontributestorenoprotectiveeffectsofangiotensiniitype1receptorblockadeindiabeticnephropathy